Form 4: United Therapeutics Exec Sells Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the sale of common stock acquired through stock option exercises, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, executed a series of transactions on May 26, 2026.
• These transactions involved the exercise of stock options and the subsequent sale of 9,500 shares of common stock at an average price of $146.03.
• Additionally, Rothblatt sold a significant number of shares under a 10b5-1 trading plan, with sales occurring at prices ranging from $559.68 to $578.39.
• The total number of shares sold in these subsequent transactions amounts to 43,153.
• Rothblatt's beneficial ownership of common stock following these transactions is detailed, with holdings directly and indirectly owned through trusts and by a spouse.
• The transactions were conducted under a 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, whichever comes first.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While significant share sales by an executive can sometimes raise concerns, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading and suggests a planned divestment strategy.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a structured and potentially pre-planned approach to managing equity holdings.
• The exercise of stock options and subsequent sale of shares at various price points suggests a strategy to realize gains from vested options.

Negatives

• A significant number of shares were sold by a key executive, which could be interpreted negatively by the market, although it was conducted under a pre-arranged plan.
• The filing details numerous individual sales transactions, indicating a substantial divestment of shares by the reporting person.

Risks

• The 10b5-1 trading plan has an expiration date of December 31, 2026, or upon the exercise of all remaining stock options, creating a defined window for these transactions.
• The underlying stock options expire on March 17, 2027, which may influence the timing and execution of the trading plan.

Future Outlook

The 10b5-1 trading plan is active until December 31, 2026, or until all 1,734,410 stock options are exercised, with options expiring on March 17, 2027. This indicates ongoing potential for further transactions under this plan within the specified timeframe.

Management Comments

• The exercise of stock options and sale of resulting shares was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for various weighted average price transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions, particularly those under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors. These plans allow executives to sell shares during blackout periods, providing transparency and mitigating insider trading concerns. The scale of these transactions can sometimes influence investor sentiment.

Stakeholder Impact

• Shareholders may observe the significant sale of shares by a key executive, which could influence short-term trading sentiment, though the 10b5-1 plan provides context for the sales.
• Employees holding stock options may be influenced by the executive's strategy for exercising and selling shares.
• Creditors and suppliers are unlikely to be directly impacted by this insider transaction filing.

Next Steps

• The 10b5-1 trading plan will continue until December 31, 2026, or until all 1,734,410 stock options are exercised.
• Further transactions may be reported on subsequent Form 4 filings if they occur under the existing plan.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Stock Options, 10b5-1 Plan, Insider Trading, Beneficial Ownership, Stock Sale, Martine Rothblatt